AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024
Nov 13, 2024
30849_dirs_2024-11-13_789ed279-80f9-4e29-8933-db724b95845d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-11-11
Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-11 | Common Stock | M | 20622 | $6.80 | Acquired | 27474 | Direct |
| 2024-11-11 | Common Stock | M | 28717 | $24.29 | Acquired | 56191 | Direct |
| 2024-11-11 | Common Stock | M | 11642 | $30.66 | Acquired | 67833 | Direct |
| 2024-11-11 | Common Stock | S | 38051 | $65.6763 | Disposed | 29782 | Direct |
| 2024-11-11 | Common Stock | S | 17540 | $66.9484 | Disposed | 12242 | Direct |
| 2024-11-11 | Common Stock | S | 11070 | $67.5585 | Disposed | 1172 | Direct |
| 2024-11-11 | Common Stock | S | 200 | $68.43 | Disposed | 972 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-11-11 | Stock Option (Right to Buy) | $6.80 | M | 20622 | Disposed | 2032-02-08 | Common Stock (20622) | Direct |
| 2024-11-11 | Stock Option (Right to Buy) | $24.29 | M | 28717 | Disposed | 2030-11-09 | Common Stock (28717) | Direct |
| 2024-11-11 | Stock Option (Right to Buy) | $30.66 | M | 11642 | Disposed | 2031-02-10 | Common Stock (11642) | Direct |
Footnotes
F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.18 to $66.1799 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $66.33 to $67.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $67.33 to $68.3299 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F6: The stock options were granted on November 9, 2020. The options are fully vested.
F7: The stock options were granted on February 11, 2021. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.